InnovAge (NASDAQ: INNV) reaffirms FY 2026 outlook at KeyBank forum

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

InnovAge Holding Corp. is meeting with investors and analysts at the KeyBank Capital Markets Healthcare Forum. During these meetings, the company expects to reaffirm its full year fiscal 2026 guidance that was previously provided in a February 3, 2026 press release about second fiscal quarter results ended December 31, 2026.

InnovAge has also posted the investor presentation used for these meetings on its Investor Relations website, making it publicly accessible. The information is being furnished under Regulation FD and is not deemed filed or incorporated by reference into other securities law filings unless specifically stated.

8-K Event Classification

Item 7.01 — Regulation FD Disclosure

1 item

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Understanding 8-K Material Events →

03/17/2026 - 08:01 AM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 17, 2026

INNOVAGE HOLDING CORP.

(Exact name of registrant as specified in its charter)


Delaware	001-40159	81-0710819
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

8950 E. Lowry Boulevard Denver, CO		80230
(Address of principal executive offices)		(Zip Code)

(844) 803-8745

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


o			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.001 par value	INNV	The Nasdaq Stock Market LLC (Nasdaq Global Select Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 7.01. Regulation FD Disclosure.

On March 17, 2026, InnovAge Holding Corp. (the “Company”) will meet with investors and analysts at the KeyBank Capital Markets Healthcare Forum. At such meetings, the Company expects to reaffirms its full year fiscal year 2026 guidance as provided in its press release issued on February 3, 2026 in connection with the announcement of the Company’s results for the second fiscal quarter ended December 31, 2026. A copy of the presentation to be used in connection with these meetings has been posted on the Company’s Investor Relations website and is accessible to the public at https://investor.innovage.com.

The information in this Item 7.01 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. This information shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference to such disclosure in this Form 8-K in such a filing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


	INNOVAGE HOLDING CORP.

Date: March 17, 2026	By:	/s/ Benjamin C. Adams
	Name:	Benjamin C. Adams
	Title:	Chief Financial Officer

Source: View Original Filing on SEC EDGAR

FAQ

What did InnovAge (INNV) announce in its latest Form 8-K?

InnovAge stated it will meet investors and analysts at the KeyBank Capital Markets Healthcare Forum and expects to reaffirm its full year fiscal 2026 guidance. The company is also making its investor presentation publicly available on its Investor Relations website for broader access.

How is InnovAge (INNV) handling its fiscal 2026 guidance in this update?

InnovAge expects to reaffirm its full year fiscal 2026 guidance that was originally provided in a February 3, 2026 press release. That guidance accompanied results for the second fiscal quarter ended December 31, 2026 and remains the framework the company is communicating to investors.

Where can investors find InnovAge’s March 2026 investor presentation?

InnovAge has posted the presentation used for meetings at the KeyBank Capital Markets Healthcare Forum on its Investor Relations website at https://investor.innovage.com. The company states this presentation is accessible to the public, allowing all investors to review the same information shared at the forum.

What is the purpose of InnovAge’s participation in the KeyBank Capital Markets Healthcare Forum?

InnovAge is meeting with investors and analysts at the KeyBank Capital Markets Healthcare Forum to discuss the business and communicate its outlook. As part of these meetings, the company expects to reaffirm previously issued full year fiscal 2026 guidance, maintaining consistency with its earlier public communication.

Is InnovAge’s guidance information in this 8-K considered filed with the SEC?

The company states that the information under Item 7.01 is furnished, not filed, for purposes of the Securities Exchange Act of 1934. It is not subject to Section 18 liabilities and will not be incorporated into other securities filings unless specifically referenced there by the company.

Which prior InnovAge disclosure is referenced regarding fiscal 2026 guidance?

InnovAge refers to its press release issued on February 3, 2026, which accompanied the announcement of results for the second fiscal quarter ended December 31, 2026. The company expects to reaffirm the full year fiscal 2026 guidance that was described in that earlier communication to the market.

Filing Exhibits & Attachments

3 documents